nach oben

Erschienen in:

05.02.2018 | Original Article

Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT

verfasst von: Judit Boda-Heggemann, MD, Anika Jahnke, PhD, Mark K. H. Chan, PhD, Leila S. Ghaderi Ardekani, MSc, Peter Hunold, MD, Jost Philipp Schäfer, MD, Stefan Huttenlocher, MD, Stefan Wurster, MD, Dirk Rades, MD, Guido Hildebrandt, MD, Frank Lohr, MD, Jürgen Dunst, MD, Frederik Wenz, MD, Oliver Blanck, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

For assessing healthy liver reactions after robotic SBRT (stereotactic body radiotherapy), we investigated early morphologic alterations on MRI (magnetic resonance imaging) with respect to patient and treatment plan parameters.

Patients and methods

MRI data at 6–17 weeks post-treatment from 22 patients with 42 liver metastases were analyzed retrospectively. Median prescription dose was 40 Gy delivered in 3–5 fractions. T2- and T1-weighted MRI were registered to the treatment plan. Absolute doses were converted to EQD2 (Equivalent dose in 2Gy fractions) with α/β-ratios of 2 and 3 Gy for healthy, and 8 Gy for modelling pre-damaged liver tissue.

Results

Sharply defined, centroid-shaped morphologic alterations were observed outside the high-dose volume surrounding the GTV. On T2-w MRI, hyperintensity at EQD2 isodoses of 113.3 ± 66.1 Gy₂, 97.5 ± 54.7 Gy₃, and 66.5 ± 32.0 Gy₈ significantly depended on PTV dimension (p = 0.02) and healthy liver EQD2 (p = 0.05). On T1-w non-contrast MRI, hypointensity at EQD2 isodoses of 113.3 ± 49.3 Gy₂, 97.4 ± 41.0 Gy₃, and 65.7 ± 24.2 Gy₈ significantly depended on prior chemotherapy (p = 0.01) and total liver volume (p = 0.05). On T1-w gadolinium-contrast delayed MRI, hypointensity at EQD2 isodoses of 90.6 ± 42.5 Gy₂, 79.3 ± 35.3 Gy₃, and 56.6 ± 20.9 Gy₈ significantly depended on total (p = 0.04) and healthy (p = 0.01) liver EQD2.

Conclusions

Early post-treatment changes in healthy liver tissue after robotic SBRT could spatially be correlated to respective isodoses. Median nominal doses of 10.1–11.3 Gy per fraction (EQD2 79–97 Gy₃) induce characteristic morphologic alterations surrounding the lesions, potentially allowing for dosimetric in-vivo accuracy assessments. Comparison to other techniques and investigations of the short- and long-term clinical impact require further research.

Sterzing F, Brunner TB, Ernst I et al (2014) Stereotactic body radiotherapy for liver tumors: principles and practical guidelines of the DEGRO Working Group on Stereotactic Radiotherapy. Strahlenther Onkol 190(10):872–881CrossRefPubMed

Boda-Heggemann J, Dinter D, Weiss C et al (2012) Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases—clinical results. Radiat Oncol 7:92CrossRefPubMedPubMedCentral

Andratschke N, Parys A, Stadtfeld S et al (2016) Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases. Radiat Oncol 11:74CrossRefPubMedPubMedCentral

Klement RJ, Guckenberger M, Alheid H et al (2017) Stereotactic body radiotherapy for oligo-metastatic liver disease – influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol 123(2):227–233CrossRefPubMed

Osmundson EC, Wu Y, Luxton G et al (2015) Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. Int J Radiat Oncol Biol Phys 91(5):986–994CrossRefPubMed

Toesca DAS, Osmundson EC, von Eyben R et al (2017) Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. Pract Radiat Oncol 7(3):173–182CrossRefPubMed

Grimm J, LaCouture T, Croce R et al (2011) Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy. J Appl Clin Med Phys 12(2):3368CrossRefPubMed

LaCouture TA, Xue J, Subedi G et al (2016) Small bowel dose tolerance for stereotactic body radiation therapy. Semin Radiat Oncol 26(2):157–164CrossRefPubMed

Goldsmith C, Price P, Cross T et al (2016) Dose-volume histogram analysis of stereotactic body radiotherapy treatment of pancreatic cancer: a focus on duodenal dose constraints. Semin Radiat Oncol 26(2):149–156CrossRefPubMed

10.

Pan CC, Kavanagh BD, Dawson LA et al (2010) Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 76(3):94–100CrossRef

11.

Jung J, Yoon SM, Kim SY et al (2013) Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters. Radiat Oncol 8:249CrossRefPubMedPubMedCentral

12.

Dreher C, Hoyer KI, Fode MM et al (2016) Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma. Acta Oncol 55(7):886–891CrossRefPubMed

13.

Barry A, McPartlin A, Lindsay P et al (2017) Dosimetric analysis of liver toxicity after liver metastasis stereotactic body radiation therapy. Pract Radiat Oncol 7(5):e331–e337. https://doi.org/10.1016/j.prro.2017.03.004 CrossRefPubMed

14.

Herfarth KK, Hof H, Bahner ML et al (2003) Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of liver tumors. Int J Radiat Oncol Biol Phys 57:444–451CrossRefPubMed

15.

Seidensticker M, Seidensticker R, Mohnike K et al (2011) Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes. Radiat Oncol 6:40CrossRefPubMedPubMedCentral

16.

Seidensticker M, Burak M, Kalinski T et al (2015) Radiation-induced liver damage: correlation of histopathology with hepatobiliary magnetic resonance imaging, a feasibility study. Cardiovasc Intervent Radiol 38:213–221CrossRefPubMed

17.

Seidensticker M, Seidensticker R, Damm R et al (2014) Prospective randomized trial of enoxaparin, pentoxifylline and ursodeoxycholic acid for prevention of radiation-induced liver toxicity. PLoS ONE 9:e112731CrossRefPubMedPubMedCentral

18.

Boda-Heggemann J, Attenberger U, Budjan J et al (2016) MRI morphologic alterations after liver SBRT: direct dose correlation with intermodal matching. Strahlenther Onkol 192(9):641–648CrossRefPubMed

19.

Sanuki-Fujimoto N, Takeda A, Ohashi T et al (2010) CT evaluations of focal liver reactions following stereotactic body radiotherapy for small hepatocellular carcinoma with cirrhosis: relationship between imaging appearance and baseline liver function. Br J Radiol 83:1063–1071CrossRefPubMedPubMedCentral

20.

Lo SS, Teh BS, Wang JZ et al (2011) Imaging changes after stereotactic body radiation therapy for lung and liver tumors. Expert Rev Anticancer Ther 11:613–620CrossRefPubMed

21.

Howells CC, Stinauer MA, Diot Q et al (2012) Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys 84:e441–446CrossRefPubMed

22.

Jarraya H, Mirabel X, Taieb S et al (2013) Image-based response assessment of liver metastases following stereotactic body radiotherapy with respiratory tracking. Radiat Oncol 8:24CrossRefPubMedPubMedCentral

23.

Richter C, Seco J, Hong TS et al (2014) Radiation-induced changes in hepatocyte-specific Gd-EOB-DTPA enhanced MRI: potential mechanism. Med Hypotheses 83:477–481CrossRefPubMed

24.

Sanuki N, Takeda A, Oku Y et al (2014) Threshold doses for focal liver reaction after stereotactic ablative body radiation therapy for small hepatocellular carcinoma depend on liver function: evaluation on magnetic resonance imaging with Gd-EOB-DTPA. Int J Radiat Oncol Biol Phys 88:306–311CrossRefPubMed

25.

Schmid-Tannwald C, Strobl FF, Theisen D et al (2015) Diffusion-weighted MRI before and after robotic radiosurgery (Cyberknife(R)) in primary and secondary liver malignancies: a pilot study. Technol Cancer Res Treat 14:191–199CrossRefPubMed

26.

Lall C, Bhargava P, Sandrasegaran K et al (2015) Three-dimensional conformal radiation therapy in the liver: MRI findings along a time continuum. J Comput Assist Tomogr 39:356–364PubMed

27.

Haddad MM, Merrell KW, Hallemeier CL et al (2016) Stereotactic body radiation therapy of liver tumors: post-treatment appearances and evaluation of treatment response: a pictorial review. Abdom Radiol (NY) 41(10):2061–2077CrossRef

28.

Doi H, Shiomi H, Masai N et al (2016) Threshold doses and prediction of visually apparent liver dysfunction after stereotactic body radiation therapy in cirrhotic and normal livers using magnetic resonance imaging. J Radiat Res 57(3):294–300CrossRefPubMedPubMedCentral

29.

Fukugawa Y, Namimoto T, Toya R et al (2017) Radiation-induced liver injury after 3D-conformal radiotherapy for hepatocellular carcinoma: quantitative assessment using Gd-EOB-DTPA-enhanced MRI. Acta Med Okayama 71(1):25–29PubMed

30.

Olsen CC, Welsh J, Kavanagh BD et al (2009) Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 73:1414–1424CrossRefPubMed

31.

Kilby W, Dooley JR, Kuduvalli G et al (2010) The CyberKnife Robotic Radiosurgery System in 2010. Technol Cancer Res Treat 9(5):433–452CrossRefPubMed

32.

Vautravers-Dewas C, Dewas S, Bonodeau F et al (2011) Image-guided robotic stereotactic body radiation therapy for liver metastases: is there a dose response relationship? Int J Radiat Oncol Biol Phys 81(3):e39–47CrossRefPubMed

33.

Méndez Romero A, Verheij J, Dwarkasing RS et al (2012) Comparison of macroscopic pathology measurements with magnetic resonance imaging and assessment of microscopic pathology extension for colorectal liver metastases. Int J Radiat Oncol Biol Phys 82(1):159–166CrossRefPubMed

34.

Chan M, Grehn M, Cremers F et al (2017) Dosimetric implications of residual tracking errors during robotic SBRT of liver metastases. Int J Radiat Oncol Biol Phys 97(4):839–848CrossRefPubMed

35.

Blanck O, Wang L, Baus W et al (2016) Inverse treatment planning for spinal robotic radiosurgery: an international multi-institutional benchmark trial. J Appl Clin Med Phys 17(3):313–330CrossRefPubMedPubMedCentral

36.

Malinowski K, McAvoy TJ, George R et al (2013) Maintaining tumor targeting accuracy in real-time motion compensation systems for respiration-induced tumor motion. Med Phys 40(7):71709CrossRefPubMedPubMedCentral

37.

Michaely HJ, Morelli JN, Budjan J et al (2013) CAIPIRINHA-Dixon-TWIST (CDT)-volume-interpolated breath-hold examination (VIBE): a new technique for fast time-resolved dynamic 3‑dimensional imaging of the abdomen with high spatial resolution. Invest Radiol 48:590–597CrossRefPubMed

38.

Morelli JN, Michaely HJ, Meyer MM et al (2013) Comparison of dynamic and liver-specific gadoxetic acid contrast-enhanced MRI versus apparent diffusion coefficients. PLoS ONE 8:e61898CrossRefPubMedPubMedCentral

39.

Kanai T, Kadoya N, Ito K et al (2014) Evaluation of accuracy of B‑spline transformation-based deformable image registration with different parameter settings for thoracic images. J Radiat Res 55:1163–1170CrossRefPubMedPubMedCentral

40.

Ger RB, Yang J, Ding Y et al (2017) Accuracy of deformable image registration on magnetic resonance images in digital and physical phantoms. Med Phys 44(10):5153–5161. https://doi.org/10.1002/mp.12406 CrossRefPubMed

41.

Fukumitsu N, Nitta K, Terunuma T et al (2017) Registration error of the liver CT using deformable image registration of MIM Maestro and Velocity AI. Bmc Med Imaging 17(1):30CrossRefPubMedPubMedCentral

42.

Milano MT, Constine LS, Okunieff P (2008) Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 3:36CrossRefPubMedPubMedCentral

43.

Dawson LA, Ten Haken RK (2005) Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 15:279–283CrossRefPubMed

44.

Son SH, Jang HS, Lee H et al (2013) Determination of the alpha/beta ratio for the normal liver on the basis of radiation-induced hepatic toxicities in patients with hepatocellular carcinoma. Radiat Oncol 8:61CrossRefPubMedPubMedCentral

45.

Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F et al (2017) Planning benchmark study for SBRT of early stage NSCLC: results of the DEGRO Working Group Stereotactic Radiotherapy. Strahlenther Onkol 193(10):780–790. https://doi.org/10.1007/s00066-017-1151-8 CrossRefPubMed

46.

Dollinger M, Jung EM, Beyer L et al (2014) Irreversible electroporation ablation of malignant hepatic tumors: subacute and follow-up CT appearance of ablation zones. J Vasc Interv Radiol 25(10):1589–1594CrossRefPubMed

47.

Cheng W, Xiao L, Ainiwaer A et al (2015) Molecular responses of radiation-induced liver damage in rats. Mol Med Rep 11(4):2592–2600CrossRefPubMed

48.

Tetreau R, Llacer C, Riou O et al (2017) Evaluation of response after SBRT for liver tumors. Rep Pract Oncol Radiother 22:170–175CrossRefPubMed

49.

Yuan Y, Andronesi OC, Bortfeld TR et al (2013) Feasibility study of in vivo MRI based dosimetric verification of proton end-of-range for liver cancer patients. Radiother Oncol 106:378–382CrossRefPubMed

50.

Pollom EL, Chin AL, Diehn M et al (2017) Normal tissue constraints for abdominal and thoracic stereotactic body radiotherapy. Semin Radiat Oncol 27(3):197–208CrossRefPubMed

Titel: Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT
verfasst von: Judit Boda-Heggemann, MD
Anika Jahnke, PhD
Mark K. H. Chan, PhD
Leila S. Ghaderi Ardekani, MSc
Peter Hunold, MD
Jost Philipp Schäfer, MD
Stefan Huttenlocher, MD
Stefan Wurster, MD
Dirk Rades, MD
Guido Hildebrandt, MD
Frank Lohr, MD
Jürgen Dunst, MD
Frederik Wenz, MD
Oliver Blanck, PhD
Publikationsdatum: 05.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 5/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1271-9

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Direct dose correlation of MRI morphologic alterations of healthy liver tissue after robotic liver SBRT